

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TIAN YUAN HEALTHCARE

天 元 医 疗

CHINA TIAN YUAN HEALTHCARE GROUP LIMITED

中國天元醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 557)

**(I) FURTHER DELAY IN PUBLICATION OF THE 2020 INTERIM RESULTS
AND THE 2020 ANNUAL RESULTS;
AND
(II) CONTINUED SUSPENSION OF TRADING**

This announcement is made by the board of directors (the “**Board**”) of China Tian Yuan Healthcare Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2)(a) and 13.49(6) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated (i) 21 August 2020 in relation to suspension of trading in the shares of the Company; (ii) 31 August 2020 in relation to postponement of board meeting; (iii) 11 September 2020 in relation to resumption guidance, and the annual report of the Company for the year ended 31 December 2019; (iv) 30 September 2020 in relation to the delay in publication of the 2020 Interim Results and the despatch of the 2020 Interim Report; (v) 15 December 2020 in relation to the further delay in publication of the 2020 Interim Results and despatch of the 2020 Interim Report; (vi) 31 March 2021 in relation to (a) the further delay in publication of the 2020 Interim Results and despatch of the 2020 Interim Report and (b) the delay in publication of the 2020 Annual Results and despatch of the 2020 Annual Report; (vii) 9 April 2021 in relation to the notification of board; (viii) 21 April 2021 in relation to the change of date of board meeting; and (ix) 22 April 2021 in relation to the clarification announcement to the change of date of board meeting (together, the “**Announcements**”).

Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as those defined in the Announcements.

FURTHER DELAY IN PUBLICATION OF THE 2020 INTERIM RESULTS AND THE 2020 ANNUAL RESULTS

The Board would like to inform the Shareholders and potential investors of the Company that the Company requires additional time to collate the information and documents of the subsidiaries required to address the request by the Company's external auditor to finalise the audit work of the 2020 Annual Results and was unable to publish the 2020 Interim Results and the 2020 Annual Results as scheduled in the week of 19 April 2021. The Company will use its best endeavours to publish the 2020 Interim Results and the 2020 Annual Results as soon as possible and will make further announcement as and when appropriate, to inform the shareholders of the Company (the "**Shareholders**") regarding the date of publication of the 2020 Interim Results and the 2020 Annual Results.

Notwithstanding this, the Board wishes to emphasise that the operation of the Group remains normal and that it will continue to work with the auditor of the Company closely with a view to publish the 2020 Annual Results as soon as possible.

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to issue its preliminary results in accordance with Rules 13.49(1) and (2) of the Listing Rules, it must announce its results based on the financial results that have yet to be agreed with the Auditors. After due and careful consideration, the Board is of the view that it may not be appropriate for the Company to publish the unaudited management accounts of the Company for the 2020 Annual Results at this stage as it may not accurately reflect the financial performance and position of the Group.

The Company will publish further announcement(s) to inform the Shareholders of any further updates on (i) the expected date of publication of the 2020 Annual Results; (ii) the date(s) of the Board meeting to consider and approve the 2020 Annual Results; and (iii) the despatch of the 2020 Annual Report as and when appropriate.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange was suspended with effect from 9:00 a.m. on Monday, 24 August 2020 and will remain suspended until further notice.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Tian Yuan Healthcare Group Limited
Zhang Xian
Executive Director

Hong Kong, 26 April 2021

As at the date of this announcement, the Board is composed of seven directors of which Mr. Wang Huabing (chairman) and Ms. Zhang Xian are the executive directors, Ms. He Mei and Mr. Zhou Yuan are the non-executive directors and Mr. Hu Baihe, Mr. Yuen Kwok Kuen and Mr. Guo Jingbin are the independent non-executive directors.